daclatasvir

Details

Files

Generic Name:

daclatasvir

Project Status:

Complete

Therapeutic Area:

Hepatitis C, Chronic

Manufacturer:

Bristol Myers Squibb Canada Inc.

Call for patient/clinician input open:

January 6, 2016

Brand Name:

Daklinza

Project Line:

Reimbursement Review

Project Number:

SF0467-000

Call for patient/clinician input closed:

February 25, 2016

NOC Status at Filing:

Post NOC

Submission Type:

Request For Advice

Indications:

Hepatitis C, chronic

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

May 19, 2016

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Request for Advice View PDF

Patient Group Input Submissions View PDF

Last Updated : January 6, 2016